Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

10,630 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,471
Recruiting: 1,282
Ph III recruiting: 129
Growth YoY: +2.6%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,643)

clinicaltrialsPublishedShowing 601–650 of 10,630 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06087653	Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)	recruiting	Phase 1 / Phase 2	24	Starton Therapeutics, IncINDUSTRY	1	Aug 24, 2026	clinicaltrials
NCT06152575	MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)	recruiting	Phase 3	492	PfizerINDUSTRY	27	Aug 24, 2026